Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced it has been selected to be in the Dow Jones Sustainability Index (DJSI) in the Emerging Markets (EM) category for its progressive Environmental, Social and Governance (ESG) practices, which underscore its commitment to the larger goal of sustainable development.
Biocon made a formal submission for Corporate Sustainability Assessment for its listing on the DJSI for the first time this year and made it to the DJSI EM Index with a Total Sustainability Score of 45 as against an industry average of 18, achieving a 93rd percentile position.
It is among the Top 15 companies from India and one of the 12 companies from the Pharmaceuticals, Biotechnology & Life Sciences sectors to be featured in the index for 2021. A total of 360 Indian companies were invited to participate in DJSI in 2021.
Sustainability has been among Biocon's topmost priorities since inception and both Biocon and Biocon Biologics are committed to provide insights into their ESG performance to their stakeholders.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said,
'Our business purpose is focused on delivering health equity by providing affordable access to life saving and essential medicines to patients across the world. Our entry in the DJSI Emerging Markets Index is a testimony to our responsible and sustainable business practices and our philosophy of putting equity and equality at the center of everything we do. The DJSI Index provides an important yardstick for Biocon and Biocon Biologics to measure sustainability performance and continuously improve reporting on ESG to address the growing interest of our global stakeholders.'
At Biocon and Biocon Biologics we have made a conscious effort to integrate environmental, social and governance agenda into the core of our business.
As a leading global biopharmaceuticals company serving millions of patients worldwide every year, Biocon is committed to lowering the cost of life-saving therapies to bring them within the reach of people who need them the most. Our philosophy of unconditional equity extends beyond research and development of innovative therapies for patients to ensuring the well-being of people, partners, customers, shareholders, local communities and the ecosystem at large.
Our operations have been designed to enable environmental sustainability with a low carbon footprint, complete recycling of wastewater and maximum use of green power. We are committed to diversity and inclusion at the workplace and are consistently endeavoring to create a collaborative and empowering work culture, in pursuit of building businesses that make a meaningful social impact. We have established globally benchmarked standards of governance to build an environment of trust, transparency and accountability.
About Dow Jones Sustainability Index
The DJSI, including the Dow Jones Sustainability World Index (DJSI World), were launched in 1999 as the pioneering series of global sustainability benchmarks available in the market. The index family is comprised of global, regional and country benchmarks. The DJSI measures the performance of companies selected using ESG criteria.
About Biocon Limited:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on Twitter: @bioconlimited
About Biocon Biologics Limited:
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non- communicable diseases. Five molecules from Biocon Biologics' portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients' worldwide. Website: www.biocon.com/businesses/biosimilars/; Follow us on Twitter: @BioconBiologics
Contact:
Biocon
Corporate Headquarters
Biocon Limited
20th KM, Hosur Road
Electronic City
Bengaluru 560100
Karnataka
India
CINL - 24234KA1978PLC003417
T: +91 80 2808 2808
T: +91 80 4014 4014
F: +91 80 2852 3423
E: contact.us@biocon.com
W: www.biocon.com
Biocon Biologics
Corporate Headquarters
Biocon Biologics Limited
Biocon House, Semicon Park
Electronics City, Phase - II, Hosur Road
Bengaluru 560100
Karnataka, India
T: +91 80 6775 6775
E: corporate.communications@biocon.com
W: www.bioconbiologics.com
BIOCON LIMITED 
